Clinical Trials and Research

OverviewTransthyretin Amyloid Cardiomyopathy (ATTR-CM) is a serious and life-threatening condition where a protein called transthyretin (TTR) misfolds and builds up…

Overview The purpose of this study is to:Determine the efficacy of nucresiran in patients with hATTR-PN by evaluating the effect on neurologic impairment,…

OverviewTransthyretin cardiac amyloidosis causes debilitating heart failure in older adults. The proposed research will develop a personalized exercise training…

Differences versus placebo seen within 30 days, sustained to 30 monthsNew analyses suggest Attruby (acoramidis) may reduce the risk of outpatient worsening heart…

OverviewThe study is conducted in participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a heart disease that occurs in people with the disease ATTR…

Transthyretin amyloid cardiomyopathy (ATTR-CM) has emerged as a significant yet frequently overlooked etiology of heart failure, particularly within the elderly…

Transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly recognized yet frequently underdiagnosed cause of heart failure, particularly among older…

AbstractCardiac amyloidosis (CA) is an infiltrative myocardiopathy caused by extracellular deposits of misfolded proteins, with evolution to heart failure (HF) and…

Findings from several studies presented at ESC Heart Failure Congress 2026 in Barcelona, Spain, were simultaneously published in JACC and JACC: Heart Failure,…

Background & AimCardiac amyloidosis is an infiltrative cardiomyopathy associated with significant morbidity and mortality. Frailty, a biologic syndrome of…